Forbius (Formation Biologics) announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support operations and Phase 2a development of AVID100, a highly potent anti-EGFR antibody-drug conjugate, in three cancer indications with significant unmet medical need.
All news from R&D
The ten-year outcomes of the Arterial Revascularisation Trial (ART) are presented today in a Hot Line Session at ESC Congress 2018. Coronary artery bypass graft (CABG) surgery is indicated in patients with angina and advanced coronary artery disease. With about one million operations per year globally, it is one of the most common major surgical procedures undertaken worldwide.
A team of Brigham and Women's Hospital researchers have developed a way to bioprint tubular structures that better mimic native vessels and ducts in the body. The 3-D bioprinting technique allows fine-tuning of the printed tissues' properties, such as number of layers and ability to transport nutrients.
These more complex tissues offer potentially viable replacements for damaged tissue. The team describes its new approach and results in a paper published in Advanced Materials.
Researchers have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells. Astrocytes play a significant role in neurodegenerative diseases. The new method reduces the time required to produce the cells from months to two weeks.
Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of a scoping review of the US Food and Drug Administration (FDA) Pilot Clinical Outcome Assessment Compendium. The results indicate that most of the patient-reported outcomes (PRO) measures sampled violate a fundamental premise of patient-focused drug development: that patients are engaged in the development.
The report, Patient-Reported Outcome Measures in the Food and Drug Administration Pilot Compendium: Meeting Today's Standards for Patient Engagement in Development?, was published in the August 2018 issue of Value in Health.
When the good and bad bacteria in our mouth become imbalanced, the bad bacteria form a biofilm (aka plaque), which can cause cavities, and if left untreated over time, can lead to cardiovascular and other inflammatory diseases like diabetes and bacterial pneumonia.
A team of researchers has recently devised a practical nanotechnology-based method for detecting and treating the harmful bacteria that cause plaque and lead to tooth decay and other detrimental conditions. The study is published in the journal Biomaterials.
The placenta has an essential and highly complex task: it must ensure the exchange of important substances between the mother and her unborn child, whilst simultaneously blocking other substances from passing through. Until now, it has not been fully understood what the permeability of the placenta depends on – after all, it is incredibly difficult to investigate its function in humans directly.
Researchers have developed another novel statistical method for evaluating gene-to-gene interactions associated with cancer and other complex diseases. The Additive-Additive 9 Interaction (AA9int) method is described in a paper published in Bioinformatics. "This method can identify combinations of genetic variants for predicting cancer risk and prognosis," notes Dr. Lin, who is also the paper's lead author.
Senescent cells are damaged cells that no longer perform their normal roles, but are not dead—hence, they are commonly known as "zombie cells." These cells interfere with the functioning of the tissue in which they accumulate.
Senescence is a cellular program that is triggered by many types of damage, and senescent cells are present in many diseases. They accumulate in diverse types of tissues during aging, thus contributing to the progressive deterioration associated with becoming elderly. Eliminating these zombie cells is one of the challenges facing science today.
There have been many setbacks on the long road to finding a treatment that might slow or stop Alzheimer's disease, but a new trial offers a glimmer of hope.
The new research has culminated in the discovery of a biomarker to identify dormant tumor cells (DTC), also known as slow-cycling cancer cells (SCCC), that, in their dormant state, go undetected by current treatments that have mostly been designed to target rapidly dividing tumor cells.
To meet their objective of offering connected devices for the physiological monitoring of laboratory animals without recourse to anesthesia or surgery, researchers from the TIMC-IMAG laboratory (CNRS / Université Grenoble Alpes / Grenoble INP / VetAgro Sup) have developed a jacket that measures rodent cardiac and respiratory activity. This patented tool soon to be released by Etisense, a TIMC-IMAG spin-off company, paves the way for enhancing the quality of research data and advancing animal welfare.